KM Research Hub

REVIEW LEDGER

论文复核台

集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。

论文元数据入排图像/No. at risk 复核依据
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.PMID 39787453 · 2025-Apr-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis.PMID 40204778 · 2025-Apr-09eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer.PMID 40106307 · 2025-Apr-01needs_reviewThe record describes a subgroup/heterogeneity analysis of a Phase III randomized trial (TITAN) comparing apalutamide vs. placebo. While it meets several criteria (oncology, human, randomized, Phase III, time-to-event endpoints), it is not the primary or definitive result report of the trial. The report type is 'subgroup', which is excluded per the rules.pending-The record describes a subgroup/heterogeneity analysis of a Phase III randomized trial (TITAN) comparing apalutamide vs. placebo. While it meets several criteria (oncology, human, randomized, Phase III, time-to-event endpoints), it is not the primary or definitive result report of the trial. The report type is 'subgroup', which is excluded per the rules.
The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials.PMID 39034169 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.PMID 39622410 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.PMID 39672382 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.PMID 39706335 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial.PMID 39833645 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Results of the Latin American Pediatric Oncology Group (GALOP-2011) Trial for Patients With Localized Ewing Sarcoma: A Multicentric Study of Interval-Compressed Multiagent Chemotherapy.PMID 39838616 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.PMID 39843940 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Population Pharmacokinetics and Exposure-Response of Subcutaneous Atezolizumab in Patients With Non-Small Cell Lung Cancer.PMID 39906948 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.PMID 39910273 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study.PMID 39914443 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial.PMID 39954568 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.PMID 40056832 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.PMID 40101606 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.PMID 40107155 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.PMID 40179906 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.PMID 40179907 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.PMID 40179908 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials.PMID 40215447 · 2025-Apreligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.PMID 39660834 · 2025-Mar-27eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial.PMID 40010135 · 2025-Mar-26eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.PMID 39693591 · 2025-Mar-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.PMID 39700442 · 2025-Mar-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Ten-Year Outcomes of a Phase 3, Multicenter, Randomized Controlled Trial (SHIP0804) With 3-Month Neoadjuvant Androgen Deprivation Prior to 125I-Seed Transperineal Prostate Brachytherapy Followed by Nil Versus 9-Month Adjuvant Hormonal Therapy in Patients With Intermediate-Risk Prostate Cancer.PMID 39551103 · 2025-Mar-15eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial.PMID 39923274 · 2025-Mar-11eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study.PMID 39952149 · 2025-Mar-11eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.PMID 40057343 · 2025-Mar-08eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, Conversion study).PMID 39690810 · 2025-Mar-05eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.PMID 39521433 · 2025-Mareligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial.PMID 39565556 · 2025-Marneeds_reviewThe record describes a Phase III randomized trial for high-risk prostate cancer, but the reported outcomes (testosterone recovery and quality of life) do not meet the criterion for survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes.pending-The record describes a Phase III randomized trial for high-risk prostate cancer, but the reported outcomes (testosterone recovery and quality of life) do not meet the criterion for survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes.
Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18).PMID 39571127 · 2025-Mareligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study.PMID 39631622 · 2025-Mareligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211.PMID 39788823 · 2025-Mareligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial.PMID 39824200 · 2025-Mareligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.PMID 39863775 · 2025-Mareligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.PMID 39893774 · 2025-Mareligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.PMID 39923717 · 2025-Mareligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial.PMID 39952264 · 2025-Mareligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.PMID 39879779 · 2025-Feb-25eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years.PMID 39671537 · 2025-Feb-20eligible命中用户提供的消化道肿瘤阳性参考集。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.PMID 39976417 · 2025-Feb-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer.PMID 39956849 · 2025-Feb-17eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing?PMID 39913282 · 2025-Feb-15eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma.PMID 39395411 · 2025-Feb-14eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Prognosis and quality of life in patients with locally advanced rectal cancer after abdominoperineal resection in the CAO/ARO/AIO-04 randomized phase 3 trial.PMID 39948076 · 2025-Feb-13eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).PMID 39442070 · 2025-Feb-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.PMID 39671534 · 2025-Feb-10eligible命中用户提供的消化道肿瘤阳性参考集。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.PMID 39798514 · 2025-Feb-05eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。